诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

休市中 05-02 16:08:25

10.440

+0.280

+2.76%

最高10.600	最低9.920	成交量204.90万
今开10.240	昨收10.160	日振幅6.69%
总市值183.85亿	流通市值156.08亿	总股本17.61亿
成交额2,112万	换手率0.14%	流通股本14.95亿
市净率2.55	ROE-6.50%	每股收益-0.28
52周最高10.960	52周最低4.220	市盈率-37.43
股息0.00	股息收益率0.00	ROA-3.52%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":10.44,"timestamp":1746173305036,"preClose":10.16,"halted":0,"volume":2049000,"delay":0,"floatShares":1495000000,"shares":1761000000,"eps":-0.27889209212932825,"marketStatus":"休市中","change":0.28,"latestTime":"05-02 16:08:25","open":10.24,"high":10.6,"low":9.92,"amount":21118541,"amplitude":0.066929,"askPrice":10.44,"askSize":574000,"bidPrice":10.42,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-0.27889209212932825,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":7,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":10.16,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0.138882,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":21.77,"timestamp":1745996400000,"preClose":20.8,"halted":0,"volume":7347000,"delay":0,"premium":"-55.29"}},"requestUrl":"/m/hq/s/09969/tweets","defaultTab":"tweets","newsList":[{"id":"2531220056","title":"诺诚健华：奥布替尼的突围赛","url":"https://stock-news.laohu8.com/highlight/detail?id=2531220056","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531220056?lang=zh_cn&edition=full","pubTime":"2025-04-30 18:29","pubTimestamp":1746008969,"startTime":"0","endTime":"0","summary":"4月28日晚间，诺诚健华发布了2024年年报，高调宣布其核心产品BTK抑制剂奥布替尼收入首次超过10亿元，迎来重大里程碑。据诺诚健华最新发布的年报，2024年奥布替尼产生的产品收益同比增长了49.1%至10.04亿元，首度跨过10亿元门槛，其中复发难治MZL适应症销售的快速增长，便是重要助力之一。截至2024年底，诺诚健华虽只有奥布替尼一款商业化产品，收入规模仍在10亿级，也仍处在净利润亏损中，却握有高达77.63亿元的现金及相关账户结余。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430221550a6cef256&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430221550a6cef256&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","688428","BK0239"],"gpt_icon":0},{"id":"2531170701","title":"诺诚健华04月30日主力净流入436.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2531170701","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531170701?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:15","pubTimestamp":1746000920,"startTime":"0","endTime":"0","summary":"04月30日, 诺诚健华股价涨3.46%，报收10.16元，成交金额1.5亿元，换手率1.01%，振幅7.54%，量比0.97。诺诚健华今日主力资金净流入436.3万元，上一交易日主力净流出296.1万元。该股近5个交易日下跌2.70%，主力资金累计净流出916.0万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入1.4亿元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170415a6ce9889&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170415a6ce9889&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09969"],"gpt_icon":0},{"id":"2531722937","title":"创新药产业链表现良好，百济神州、诺诚健华、恒瑞医药等持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2531722937","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531722937?lang=zh_cn&edition=full","pubTime":"2025-04-30 14:14","pubTimestamp":1745993640,"startTime":"0","endTime":"0","summary":"创新药产业链表现强劲，多家企业如百济神州、诺诚健华和恒瑞医药等持续活跃。百济神州2024年营收同比增长56.19%，核心产品泽布替尼和替雷利珠单抗收入显著增长，预计2025年实现全年经营利润为正。诺诚健华的BCL2抑制剂ICP-248片拟纳入突破性治疗品种，奥布替尼新适应症获批用于一线治疗CLL/SLL。锦波生物2024年营收同比增长84.92%。机构看好创新药产业链在2024年的持续良好表现，认为医药行业将迎来结构性机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142522974b2a83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142522974b2a83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0196","BK0239","09969","LU2488822045.USD","688235","BK0060","LU1969619763.USD","600276","ONC","LU2148510915.USD","LU1064131003.USD","BK0012","LU2328871848.SGD","BK0183","06160","BK0188","LU1328615791.USD","688428","159992","LU0405327148.USD","LU0405327494.USD","LU1064130708.USD","BK0028"],"gpt_icon":0},{"id":"2531776616","title":"诺诚健华盘中异动 下午盘大幅拉升5.09%报10.320港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531776616","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531776616?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:30","pubTimestamp":1745991009,"startTime":"0","endTime":"0","summary":"2025年04月30日下午盘13时30分，诺诚健华股票出现异动，股价快速拉升5.09%。截至发稿，该股报10.320港元/股，成交量913.15万股，换手率0.61%，振幅6.92%。资金方面，该股资金流入4989.44万港元，流出2707.22万港元。机构评级方面，在所有9家参与评级的机构中，89%的券商给予买入建议，11%的券商给予持有建议，无券商给予卖出建议。诺诚健华股票所在的生物技术行业中，整体涨幅为1.56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430133009a46d30fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430133009a46d30fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2531735757","title":"A股创新药概念持续走强，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制药、华东医药、恒瑞医药等涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2531735757","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531735757?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:13","pubTimestamp":1745990033,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0175","BK1500","LU0405327494.USD","688382","000963","BK0132","LU1064131003.USD","LU1969619763.USD","600276","BK0060","BK0196","BK4139","BK0012","LU1064130708.USD","LU1328615791.USD","LU0405327148.USD","688235","BK0188","06160","BK0187","BK0239","159982","BK0209","BK0183","BK1588","BK0028","002422","LU0307460666.USD","LU2328871848.SGD","688266","06978","159992","688428","BK1161","LU0588546209.SGD","LU2148510915.USD","ONC","BK1574","09969","BK1583","399300","LU2488822045.USD"],"gpt_icon":0},{"id":"2531295237","title":"港股异动 | 诺诚健华(09969)现涨超4% BCL2抑制剂拟纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2531295237","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531295237?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:15","pubTimestamp":1745982929,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华现涨超4%，截至发稿，涨3.87%，报10.2港元，成交额6223.56万港元。公开资料显示，这是诺诚健华研发的BCL2抑制剂。此外，诺诚健华近日公告称，公司自主研发的核心产品宜诺凯获得国家药监局批准，用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","BK1161","BK0239","09969","BK1574"],"gpt_icon":0},{"id":"1156609182","title":"港股异动 | 生物技术股走强，康希诺生物涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156609182","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156609182?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:13","pubTimestamp":1745982808,"startTime":"0","endTime":"0","summary":"4月30日，港股生物技术股盘中走强，$康希诺生物(06185)$涨超10%，$百济神州(06160$涨超6%，$诺诚健华(09969)$涨超4%，$泰格医药(03347)$涨超3%。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","03347","06160","06185"],"gpt_icon":0},{"id":"2531726021","title":"港股生物技术股多数走强，康希诺生物(06185.HK)涨超10%，百济神州(06160.HK)涨超6%，诺诚健华(099","url":"https://stock-news.laohu8.com/highlight/detail?id=2531726021","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531726021?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:11","pubTimestamp":1745982713,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0588546209.SGD","300347","YANG","BK1583","BK1515","06160","HSCEI","09969","LU2328871848.SGD","03347","06185","07226","688428","LU1969619763.USD","BK1500","BK1576","BK0028","BK1574","BK0239","LU1146622755.USD","BK0077","BK1141","BK1191","LU0307460666.USD","BK0216","ONC","BK1161","HSTECH","BK4139","BK4614","BK0174","BK1588","LU1820825898.SGD","688235"],"gpt_icon":0},{"id":"2531749301","title":"诺诚健华BCL2抑制剂拟纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2531749301","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531749301?lang=zh_cn&edition=full","pubTime":"2025-04-30 07:32","pubTimestamp":1745969531,"startTime":"0","endTime":"0","summary":"公开资料显示，这是诺诚健华研发的BCL2抑制剂。此外，诺诚健华的血液瘤管线也能发挥协同效应，尤其是BTK和BCL2抑制剂的联用有望为血液瘤患者带来更大获益。本次ICP-248片拟纳入突破性治疗品种的适应症为：既往接受过免疫化疗和BTK抑制剂治疗的r/r MCL患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430084621a6ce0a9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430084621a6ce0a9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","09969","688428"],"gpt_icon":0},{"id":"2531482732","title":"诺诚健华：产品获批，股价涨 1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531482732","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531482732?lang=zh_cn&edition=full","pubTime":"2025-04-29 11:03","pubTimestamp":1745895825,"startTime":"0","endTime":"0","summary":"【诺诚健华盘中股价变动，核心产品获新批准】诺诚健华盘中涨超 3%，截至发稿，股价上涨 1.34%，现报 9.85 港元，成交额 1195.82 万港元。近日，诺诚健华公告称，其核心产品宜诺凯抑制剂获得中国国家药品监督管理局批准，用于一线治疗慢性淋巴细胞白血病╱小淋巴细胞淋巴瘤患者。奥布替尼也被《中国临床肿瘤学会淋巴瘤诊疗指南 2025》列为 CLL/SLL 一线治疗的 I 级推荐方案。此前，奥布替尼已在中国获批用于治疗既往至少接受过一次治疗的 CLL/SLL、套细胞淋巴瘤和边缘区淋巴瘤，三项适应症均已纳入国家医保药品目录。此次一线 CLL/SLL 的获批将惠及更多淋巴瘤患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042911133094e6cf2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042911133094e6cf2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","09969","688428"],"gpt_icon":0},{"id":"2531219339","title":"港股异动 | 诺诚健华(09969)涨超3% 奥布替尼在中国获批用于CLL/SLL一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2531219339","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531219339?lang=zh_cn&edition=full","pubTime":"2025-04-29 09:54","pubTimestamp":1745891643,"startTime":"0","endTime":"0","summary":"消息面上，近日，诺诚健华发布公告，核心产品宜诺凯获得中国国家药品监督管理局批准，用于一线治疗慢性淋巴细胞白血病╱小淋巴细胞淋巴瘤患者。奥布替尼也被《中国临床肿瘤学会淋巴瘤诊疗指南2025》列为CLL/SLL一线治疗的I级推荐方案。此前，奥布替尼已在中国获批用于治疗既往至少接受过一次治疗的CLL/SLL、套细胞淋巴瘤和边缘区淋巴瘤，三项适应症均已纳入国家医保药品目录。此次一线CLL/SLL的获批将惠及更多淋巴瘤患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK0239","688428","BK1574","BK1161"],"gpt_icon":0},{"id":"2530473767","title":"诺诚健华：将于2025年6月20日召开2025年股东周年大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2530473767","media":"公司公告","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530473767?lang=zh_cn&edition=full","pubTime":"2025-04-28 18:15","pubTimestamp":1745835313,"startTime":"0","endTime":"0","summary":"诺诚健华公告，公司将于2025年6月20日召开股东周年大会，会议将采用现场投票与网络投票相结合的方式。会议地点为北京市昌平区 中关村 生命科学园生命园路8号院8号楼，网络投票通过上海证券交易所股东大会网络投票系统进行。会议将审议包括2024年度财务报表、利润分配计划、董事选举及授权等16项议案。参会股东需于股权登记日2025年6月16日登记在册，并可通过现场、信函、传真或邮件方式完成会议登记。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428182041a6cb7881&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428182041a6cb7881&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","688428","BK0239"],"gpt_icon":0},{"id":"2530424970","title":"诺诚健华将于5月13日举行董事会会议以审批第一季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2530424970","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530424970?lang=zh_cn&edition=full","pubTime":"2025-04-28 16:59","pubTimestamp":1745830786,"startTime":"0","endTime":"0","summary":"格隆汇4月28日丨诺诚健华(09969.HK)公布，公司将于2025年5月13日举行董事会会议，藉以（其中包括）考虑及批准公司及其附属公司截至2025年3月31日止三个月的未经审核第一季度业绩及其发布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042817000297483bac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042817000297483bac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2530485154","title":"诺诚健华奥布替尼获NMPA批准，一线治疗CLL/SLL惠及更多患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2530485154","media":"亿欧网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530485154?lang=zh_cn&edition=full","pubTime":"2025-04-27 13:50","pubTimestamp":1745733038,"startTime":"0","endTime":"0","summary":"诺诚健华 今日宣布，其自主研发的新型BTK抑制剂奥布替尼已获得中国国家药品监督管理局的批准，用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。此次批准标志着奥布替尼在CLL/SLL治疗领域的重大突破，将为更多淋巴瘤患者带来一线治疗的新选择。在此之前，奥布替尼已在中国获得批准，用于治疗既往至少接受过一次治疗的CLL/SLL、套细胞淋巴瘤和边缘区淋巴瘤，三项适应症均已纳入国家医保体系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427140038a468d381&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427140038a468d381&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","09969","688428"],"gpt_icon":0},{"id":"2530990102","title":"诺诚健华(09969)：奥布替尼在中国获批用于CLL/SLL一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2530990102","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530990102?lang=zh_cn&edition=full","pubTime":"2025-04-25 17:57","pubTimestamp":1745575063,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)公布，核心产品宜诺凯® (奥布替尼，布鲁顿酪氨酸激酶(BTK)抑制剂)获得中国国家药品监督管理局(NMPA)批准，用于一线治疗慢性淋巴细胞白血病╱小淋巴细胞淋巴瘤(CLL/SLL)患者。奥布替尼也被《中国临床肿瘤学会(CSCO)淋巴瘤诊疗指南2025》列为CLL/SLL一线治疗的I级推荐方案。此前，奥布替尼已在中国获批用于治疗既往至少接受过一次治疗的CLL/SLL、套细胞淋巴瘤(r/r MCL)和边缘区淋巴瘤(r/r MZL)，三项适应症均已纳入国家医保药品目录。此次一线CLL/SLL的获批将惠及更多淋巴瘤患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","BK1161","BK0239","09969","BK1574"],"gpt_icon":0},{"id":"2530909340","title":"诺诚健华04月25日遭主力抛售472万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530909340","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530909340?lang=zh_cn&edition=full","pubTime":"2025-04-25 16:15","pubTimestamp":1745568946,"startTime":"0","endTime":"0","summary":"04月25日, 诺诚健华股价跌3.61%，报收10.14元，成交金额1.25亿元，换手率0.82%，振幅7.41%，量比0.51。诺诚健华今日主力资金净流出472万元，上一交易日主力净流出440万元。该股近5个交易日上涨22.85%，主力资金累计净流入1.09亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1.40亿元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170200a6c7cd4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170200a6c7cd4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2530196973","title":"诺诚健华2024年报点评：奥布替尼销售超预期，多项3期临床快速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2530196973","media":"西部证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530196973?lang=zh_cn&edition=full","pubTime":"2025-04-25 15:16","pubTimestamp":1745565380,"startTime":"0","endTime":"0","summary":"SH)发布的2024年报显示，其核心产品奥布替尼全年实现收入10.00亿元，同比增长49.14%，超出市场预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425152809a6c7acbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425152809a6c7acbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2530945578","title":"诺诚健华盘中异动 早盘股价大跌5.04%报9.990港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530945578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530945578?lang=zh_cn&edition=full","pubTime":"2025-04-25 10:23","pubTimestamp":1745547819,"startTime":"0","endTime":"0","summary":"2025年04月25日早盘10时23分，诺诚健华股票出现波动，股价大幅下挫5.04%。截至发稿，该股报9.990港元/股，成交量444.9万股，换手率0.30%，振幅7.32%。资金方面，该股资金流入1881.5万港元，流出2179.88万港元。诺诚健华股票所在的生物技术行业中，整体跌幅为1.39%。其相关个股中，三叶草生物-B、晶泰控股、华康生物医学涨幅较大，振幅较大的相关个股有来凯医药-B、创胜集团-B、三叶草生物-B，振幅分别为11.68%、10.94%、9.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042510233994e1cec1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042510233994e1cec1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","BK1574","688428"],"gpt_icon":0},{"id":"2529029345","title":"强生、康乐卫士新药报产,诺诚健华1类新药纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2529029345","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529029345?lang=zh_cn&edition=full","pubTime":"2025-04-23 19:42","pubTimestamp":1745408545,"startTime":"0","endTime":"0","summary":"2020年10月，康乐卫士启动了三价HPV疫苗的III期临床试验。诺诚健华卓乐替尼片拟纳入优先审评今日，CDE官网显示，诺诚健华申报的1类新药卓乐替尼片上市申请拟纳入优先审评，适用于下列条件的成人和12岁及以上青少年实体瘤患者：携带神经营养酪氨酸受体激酶融合基因 患有局部晚期、转移性疾病或手术切除可能导致严重并发症的以及无满意替代治疗或既往治疗失败的患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423195549a6c52354&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423195549a6c52354&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","JNJ","BK1161"],"gpt_icon":0},{"id":"2529594798","title":"诺诚健华盘中异动 早盘股价大跌6.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529594798","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529594798?lang=zh_cn&edition=full","pubTime":"2025-04-23 09:35","pubTimestamp":1745372125,"startTime":"0","endTime":"0","summary":"2025年04月23日早盘09时35分，诺诚健华股票出现异动，股价急速下跌6.48%。截至发稿，该股报9.820港元/股，成交量223.1万股，换手率0.15%，振幅13.90%。资金方面，该股资金流入666.157万港元，流出1432.12万港元。诺诚健华股票所在的生物技术行业中，整体涨幅为2.51%。其相关个股中，欧康维视生物-B、康方生物、荃信生物-B涨幅较大，振幅较大的相关个股有诺诚健华、帝王国际投资、宜明昂科-B，振幅分别为13.90%、12.50%、10.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042309352594ded903&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042309352594ded903&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","688428","BK0239"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.0296},{"period":"1month","weight":0.1142},{"period":"3month","weight":0.8879},{"period":"6month","weight":0.5866},{"period":"1year","weight":0.9924},{"period":"ytd","weight":0.7059}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":-0.0301},{"period":"3month","weight":0.1127},{"period":"6month","weight":0.0974},{"period":"1year","weight":0.236},{"period":"ytd","weight":0.1219}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在巨大未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫病。该公司还在开发用于治疗由B细胞或T细胞功能异常所导致的自身免疫性疾病的产品。该公司主要在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.115368},{"month":2,"riseRate":0.6,"avgChangeRate":0.148393},{"month":3,"riseRate":0,"avgChangeRate":-0.036551},{"month":4,"riseRate":0.666667,"avgChangeRate":0.116223},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.056044},{"month":6,"riseRate":0.8,"avgChangeRate":0.122586},{"month":7,"riseRate":0.4,"avgChangeRate":-0.028005},{"month":8,"riseRate":0.2,"avgChangeRate":-0.086099},{"month":9,"riseRate":0.2,"avgChangeRate":-0.051427},{"month":10,"riseRate":0.4,"avgChangeRate":0.007797},{"month":11,"riseRate":0.8,"avgChangeRate":0.112999},{"month":12,"riseRate":0.6,"avgChangeRate":0.018835}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}